640 related articles for article (PubMed ID: 19245679)
1. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
Taylor DM; Smith L
Acta Psychiatr Scand; 2009 Jun; 119(6):419-25. PubMed ID: 19245679
[TBL] [Abstract][Full Text] [Related]
2. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
3. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of clozapine with a second antipsychotic - a meta-analysis.
Taylor DM; Smith L; Gee SH; Nielsen J
Acta Psychiatr Scand; 2012 Jan; 125(1):15-24. PubMed ID: 22077319
[TBL] [Abstract][Full Text] [Related]
5. Clinical effects of a randomized switch of patients from clozaril to generic clozapine.
Kluznik JC; Walbek NH; Farnsworth MG; Melstrom K
J Clin Psychiatry; 2001; 62 Suppl 5():14-7; discussion 23-4. PubMed ID: 11305843
[TBL] [Abstract][Full Text] [Related]
6. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
[TBL] [Abstract][Full Text] [Related]
7. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis.
Paton C; Whittington C; Barnes TR
J Clin Psychopharmacol; 2007 Apr; 27(2):198-204. PubMed ID: 17414246
[TBL] [Abstract][Full Text] [Related]
8. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine.
Munro J; Matthiasson P; Osborne S; Travis M; Purcell S; Cobb AM; Launer M; Beer MD; Kerwin R
Acta Psychiatr Scand; 2004 Oct; 110(4):292-8. PubMed ID: 15352931
[TBL] [Abstract][Full Text] [Related]
9. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
[TBL] [Abstract][Full Text] [Related]
10. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.
Henderson DC; Goff DC
J Clin Psychiatry; 1996 Sep; 57(9):395-7. PubMed ID: 9746446
[TBL] [Abstract][Full Text] [Related]
11. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study.
Stryjer R; Strous R; Bar F; Shaked G; Shiloh R; Rozencwaig S; Grupper D; Buchman N; Kotler M; Rabey JM; Weizman A
Hum Psychopharmacol; 2004 Jul; 19(5):343-6. PubMed ID: 15252826
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
[TBL] [Abstract][Full Text] [Related]
13. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation.
Raskin S; Katz G; Zislin Z; Knobler HY; Durst R
Acta Psychiatr Scand; 2000 Apr; 101(4):334-6. PubMed ID: 10782556
[TBL] [Abstract][Full Text] [Related]
14. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study.
Nielsen J; Emborg C; Gydesen S; Dybbro J; Aagaard J; Haderup K; Glyngdal P; Fabricius S; Thode D; Lublin H; Andersen T; Damkier P; Taylor D
J Clin Psychopharmacol; 2012 Apr; 32(2):173-8. PubMed ID: 22367659
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Zink M; Kuwilsky A; Krumm B; Dressing H
J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
[TBL] [Abstract][Full Text] [Related]
16. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients.
Schulz SC; Thompson PA; Jacobs M; Ninan PT; Robinson D; Weiden PJ; Yadalam K; Glick ID; Odbert CL
J Clin Psychiatry; 1999 Jun; 60(6):366-72. PubMed ID: 10401914
[TBL] [Abstract][Full Text] [Related]
17. The brief psychiatric rating scale: effect of scaling system on clinical response assessment.
Thompson PA; Buckley PF; Meltzer HY
J Clin Psychopharmacol; 1994 Oct; 14(5):344-6. PubMed ID: 7806691
[TBL] [Abstract][Full Text] [Related]
18. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression.
Welge JA; Keck PE
Psychopharmacology (Berl); 2003 Feb; 166(1):1-10. PubMed ID: 12494247
[TBL] [Abstract][Full Text] [Related]
19. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.
Semiz UB; Cetin M; Basoglu C; Ebrinc S; Uzun O; Herken H; Balibey H; Algul A; Ates A
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1330-6. PubMed ID: 17618026
[TBL] [Abstract][Full Text] [Related]
20. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
